SCHEMBL1127093

SCHEMBL1127093

CCOC(=O)c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
POLB P06746 2/20 0.58
KMT2A Q03164 2/20 0.57
MAPT P10636 3/20 0.54
ALDH1A1 P00352 3/20 0.52
TCF4 P15884 1/20 0.52
CTNNB1 P35222 1/20 0.52
TSHR P16473 1/20 0.52
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
KDM4E B2RXH2 1/20 0.51
TP53 P04637 2/20 0.51
THRB P10828 1/20 0.51
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17343057 0.88 TSHR (0.62) LMNASMN1; SMN2POLBKMT2AMAPT
SCHEMBL7570489 0.84 LMNA (0.52) LMNASMN1; SMN2KMT2AMAPTALDH1A1
SCHEMBL1126923 0.84 LMNA (0.54) LMNASMN1; SMN2KMT2AMAPTALDH1A1
SCHEMBL1726857 0.82 LMNA (0.76) LMNASMN1; SMN2POLBKMT2AMAPT
SCHEMBL3560486 0.81 POLB (0.73) LMNASMN1; SMN2POLBKMT2AMAPT
SCHEMBL4823240 0.81 HPGD (0.68) LMNASMN1; SMN2POLBKMT2AMAPT
SCHEMBL17331309 0.81 TCF4 (0.79) LMNASMN1; SMN2POLBKMT2AMAPT
SCHEMBL399284 0.81 LMNA (0.64) LMNASMN1; SMN2POLBMAPTALDH1A1
SCHEMBL134279 0.80 SMN1; SMN2 (0.62) LMNASMN1; SMN2POLBKMT2AMAPT
SCHEMBL16119561 0.80 LMNA (0.77) LMNASMN1; SMN2POLBKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073341-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2017-03-16 US disclosed
US-20170073341-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2017-03-16 US disclosed
US-20170073341-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2017-03-16 US disclosed
EP-3106462-A1 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS Novartis AG (CH) 2016-12-21 EP disclosed
EP-3106462-A1 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS Novartis AG (CH) 2016-12-21 EP disclosed
EP-2282636-B1 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS NOVARTIS AG (CH) 2016-03-23 EP disclosed
EP-2282636-B1 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS NOVARTIS AG (CH) 2016-03-23 EP disclosed
US-20160068523-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2016-03-10 US disclosed
US-20160068523-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2016-03-10 US disclosed
US-9233956-B2 Benzene sulfonamide thiazole and oxazole compounds NOVARTIS AG (CH) 2016-01-12 US disclosed
US-20110172215-A1 Benzene Sulfonamide Thiazole And Oxazole Compounds NOVARTIS AG (CH) 2011-07-14 US disclosed
US-20110172215-A1 Benzene Sulfonamide Thiazole And Oxazole Compounds NOVARTIS AG (CH) 2011-07-14 US disclosed
EP-2282636-A2 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS GlaxoSmithKline LLC (US) 2011-02-16 EP disclosed
WO-2010104899-A1 THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-09-16 WO disclosed
WO-2010104899-A1 THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-09-16 WO disclosed
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2009-12-03 US disclosed
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2009-12-03 US disclosed
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds NOVARTIS AG (CH) 2009-12-03 US disclosed
WO-2009137391-A2 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-12 WO disclosed
WO-2009137391-A2 BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172215-A1 Benzene Sulfonamide Thiazole And Oxazole Compounds STS, TST, TPST2 LMNA 3854/4885SMN1; SMN2 2314/4885POLB 3156/4885
US-20170073341-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds STS, TST, TPST2 LMNA 3854/4885SMN1; SMN2 2314/4885POLB 3156/4885
US-20160068523-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds STS, TST, TPST2 LMNA 3854/4885SMN1; SMN2 2314/4885POLB 3156/4885
US-20090298815-A1 Benzene Sulfonamide Thiazole and Oxazole Compounds STS, TST, TPST2 LMNA 3854/4885SMN1; SMN2 2314/4885POLB 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.